These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

742 related items for PubMed ID: 25835443

  • 1. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators.
    J Am Coll Cardiol; 2015 Apr 07; 65(13):1314-1321. PubMed ID: 25835443
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators.
    Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612
    [Abstract] [Full Text] [Related]

  • 3. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators.
    J Am Coll Cardiol; 2014 Sep 16; 64(11):1071-8. PubMed ID: 24858423
    [Abstract] [Full Text] [Related]

  • 4. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL.
    Hypertension; 2015 Dec 16; 66(6):1130-7. PubMed ID: 26558819
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S, Cohen SA, Fahy M, Pilcher G, Kario K, SPYRAL HTN-ON MED Trial Investigators.
    Lancet; 2018 Jun 09; 391(10137):2346-2355. PubMed ID: 29803589
    [Abstract] [Full Text] [Related]

  • 7. Renal denervation in moderate treatment-resistant hypertension.
    Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE.
    J Am Coll Cardiol; 2013 Nov 12; 62(20):1880-6. PubMed ID: 23850901
    [Abstract] [Full Text] [Related]

  • 8. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.
    Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G, GSR Investigators.
    Hypertension; 2015 Apr 12; 65(4):766-74. PubMed ID: 25691618
    [Abstract] [Full Text] [Related]

  • 9. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    Symplicity HTN-2 InvestigatorsBaker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road, Central Melbourne, VIC 8008, Australia. murray.esler@bakeridi.edu.au, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M.
    Lancet; 2010 Dec 04; 376(9756):1903-9. PubMed ID: 21093036
    [Abstract] [Full Text] [Related]

  • 10. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.
    Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA, Symplicity HTN-2 Investigators.
    Circulation; 2012 Dec 18; 126(25):2976-82. PubMed ID: 23248063
    [Abstract] [Full Text] [Related]

  • 11. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L, Kario K, Basile J, Daemen J, Davies J, Kirtane AJ, Mahfoud F, Schmieder RE, Weber M, Nanto S, Azizi M.
    Am Heart J; 2018 Jan 18; 195():115-129. PubMed ID: 29224639
    [Abstract] [Full Text] [Related]

  • 12. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients - .
    Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K, SYMPLICITY HTN-Japan Investigators.
    Circ J; 2015 Jan 18; 79(6):1222-9. PubMed ID: 25912693
    [Abstract] [Full Text] [Related]

  • 13. Renal denervation in patients with resistant hypertension: six-month results.
    Dores H, de Sousa Almeida M, de Araújo Gonçalves P, Branco P, Gaspar A, Sousa H, Canha Gomes A, Andrade MJ, Carvalho MS, Campante Teles R, Raposo L, Mesquita Gabriel H, Pereira Machado F, Mendes M.
    Rev Port Cardiol; 2014 Apr 18; 33(4):197-204. PubMed ID: 24472425
    [Abstract] [Full Text] [Related]

  • 14. A controlled trial of renal denervation for resistant hypertension.
    Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators.
    N Engl J Med; 2014 Apr 10; 370(15):1393-401. PubMed ID: 24678939
    [Abstract] [Full Text] [Related]

  • 15. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
    Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P.
    Hypertension; 2015 Jun 10; 65(6):1202-8. PubMed ID: 25824248
    [Abstract] [Full Text] [Related]

  • 16. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
    Yerasi C, Baker NC, Jonnalagadda AK, Torguson R, Singh S, Vies J, Waksman R.
    J Am Soc Hypertens; 2015 Dec 10; 9(12):959-65. PubMed ID: 26687550
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Dimitriadis K, Choi JW, East C, D'Souza R, Sharp ASP, Ewen S, Walton A, Hopper I, Brar S, McKenna P, Fahy M, Böhm M.
    Lancet; 2022 Apr 09; 399(10333):1401-1410. PubMed ID: 35390320
    [Abstract] [Full Text] [Related]

  • 18. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
    Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M.
    Circulation; 2013 Jul 09; 128(2):132-40. PubMed ID: 23780578
    [Abstract] [Full Text] [Related]

  • 19. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension.
    Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, Mendelsohn F, Bouchard A, Larrain G, Haase M, Diaz-Cartelle J, Leon MB.
    JACC Cardiovasc Interv; 2020 Feb 24; 13(4):461-470. PubMed ID: 32081240
    [Abstract] [Full Text] [Related]

  • 20. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
    Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F, Schmieder RE, Basile J, Bloch MJ, Saxena M, Wang Y, Sanghvi K, Jenkins JS, Devireddy C, Rader F, Gosse P, Claude L, Augustin DA, McClure CK, Kirtane AJ, RADIANCE Investigators.
    Circulation; 2024 Mar 05; 149(10):747-759. PubMed ID: 37883784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.